Results 41 to 50 of about 13,727 (197)

Impact of Financial Considerations on Willingness to Take Sacubitril/Valsartan for Heart Failure

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Sacubitril/valsartan improves health outcomes for heart failure with reduced ejection fraction relative to angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers, but it carries higher out‐of‐pocket costs. Neither the impact
Birju R. Rao, Candace D. Speight, Larry A. Allen, Scott D. Halpern, Yi‐An Ko, Daniel D. Matlock, Miranda A. Moore, Alanna A. Morris, Laura D. Scherer, Mary C. Thomson, Peter Ubel, Neal W. Dickert   +11 more
doaj   +1 more source

Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF [PDF]

, 2017
Aims: Elevated serum uric acid concentration (SUA) has been associated with an increased risk of cardiovascular disease, but this may be due to unmeasured confounders.
Chen, Chen-Huan, Desai, Akshay S., Dukát, Andrej, Jhund, Pardeep S., Kristensen, Søren L., Køber, Lars, Lefkowitz, Martin P., McMurray, John J.V., Mogensen, Ulrik M., Packer, Milton, Prescott, Margaret F., Ramires, Felix, Rouleau, Jean L., Senni, Michele, Shi, Victor C., Solomon, Scott D., Swedberg, Karl   +16 more
core   +3 more sources

Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts

Scientific Reports, 2021
Left ventricular remodeling due to pressure overload is associated with poor prognosis. Sacubitril/valsartan is the first-in-class Angiotensin Receptor Neprilysin Inhibitor and has been demonstrated to have superior beneficial effects in the settings of ...
Xiaofei Li, Julie Braza, Ulrike Mende, Gaurav Choudhary, Peng Zhang   +4 more
doaj   +1 more source

Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients [PDF]

, 2017
Heart failure is a term used to define a constellation of symptoms and signs that are commonly attributed to the inability of the heart to produce a cardiac output that meets the demands of the body. It remains a deadly disease, affecting between 1-2% of
Lang, C. C., Zaid Iskandar, M.
core   +2 more sources

Combined Angiotensin Receptor–Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
BackgroundThere is a paucity of data about the mechanisms by which sacubitril/valsartan (also known as LCZ696) improves outcomes in patients with heart failure. Specifically, the effects of sacubitril/valsartan on vascular function and NO bioavailability
Rishi K. Trivedi, David J. Polhemus, Zhen Li, Daniel Yoo, Hiroshi Koiwaya, Amy Scarborough, Traci T. Goodchild, David J. Lefer   +7 more
doaj   +1 more source

Sacubitril/valsartan:beyond natriuretic peptides [PDF]

, 2017
Natriuretic peptides, especially B-type natriuretic peptide (BNP), have primarily been regarded as biomarkers in heart failure (HF). However, they are also possible therapeutic agents due to potentially beneficial physiological effects.
Atlas, Bateman, Cannon, Carpentier, Cohn, Daniels, Dehlin, Dell’Italia, Emdin, Fan, Gainer, Graf, Hirata, Hubers, Ibebuogu, Kalra, Kon, Laine, Langenickel, Liang, Maack, McMurray, McMurray, McMurray, Meilandt, Miller, Mione, Mistry, Nagaya, Niederkofler, Ohno-Matsui, Okolicany, Packer, Parthasarathy, Pelc, Potter, Potter, Rechardt, Richards, Richards, Singh, Tom, Tsutamoto, Vardeny, Vodovar, Witherow, Wong, Yasojima, Zile   +48 more
core   +2 more sources

Potential and Limitations of Atrial Natriuretic Peptide as Biomarker in Pediatric Heart Failure—A Comparative Review

Frontiers in Pediatrics, 2019
Although B-type Natriuretic Peptide (BNP), N-terminal-proBNP (NT-proBNP), and mid-regional-proANP (MR-proANP) are included in current guidelines on heart failure in adults, no guideline considering these biomarkers in pediatric heart failure is available.
Tanja Gangnus, Bjoern B. Burckhardt
doaj   +1 more source

Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization [PDF]

, 2016
Purpose: Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA class II ...
Iris Rajman, Jesika Petruck, Kiran Kode, Parasar Pal, Pierre Jordaan, Priya Chandra, Soniya Vaidya, Thomas H. Langenickel   +7 more
core   +1 more source

MELD score predicts outcomes in patients with advanced heart failure: A longitudinal evaluation

ESC Heart Failure, Volume 12, Issue 2, Page 839-847, April 2025.
Abstract Aims Advanced heart failure (AHF) is characterized by recurrent episodes of haemodynamic instability and frequent hospitalizations, leading to a progressive decline in quality of life and high mortality rates. The objectives of this study were to evaluate the effect of the model for end‐stage liver disease (MELD) score and its variations in ...
Francesco Curcio, Cristiano Amarelli, Rosaria Chiappetti, Irene Mattucci, Veronica Flocco, Mahmoud Issa Rammal, Ciro Abete, Francesca Mazzella, Ciro Maiello, Pasquale Abete, Francesco Cacciatore   +10 more
wiley   +1 more source

Sakubitriili ja valsartaani kombinatsioon südamepuudulikkuse ravis Eestis [PDF]

, 2018
Eesti Arst 2018; 97(2):95 ...
Irs, Alar
core   +2 more sources